Page 71 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine Immunochemoradiotherapy in malignant pleural mesothelioma

https://doi.org/10.3390/ijms222011192 mesothelioma. Semin Nucl Med, 52: 816–823.
7. Armato SG 3 , Labby ZE, Coolen J, et al., 2013, Imaging https://doi.org/10.1053/j.semnuclmed.2022.04.008
rd
in pleural mesothelioma: A review of the 11 International 14. Kitajima K, Doi H, Kuribayashi K, 2016, Present and future
th
Conference of the International Mesothelioma Interest roles of FDG-PET/CT imaging in the management of
Group. Lung Cancer, 82: 190–196. malignant pleural mesothelioma. Jpn J Radiol, 34: 537–547.
https://doi.org/10.1016/j.lungcan.2013.08.005 https://doi.org/10.1007/s11604-016-0555-1
8. Armato SG 3 , Ogarek JL, Starkey A, et al., 2006, Variability 15. Dong A, Zhao B, Cheng C, et al., 2022, 68 Ga-FAPI-04 versus
rd
in mesothelioma tumor response classification. AJR Am J 18 F-FDG PET/CT in detection of epithelioid malignant
Roentgenol, 186: 1000–1006. pleural mesothelioma. Clin Nucl Med, 47: 980–981.
https://doi.org/10.2214/AJR.05.0076 https://doi.org/10.1097/RLU.0000000000004269
9. Oxnard GR, Armato SG 3 , Kindler HL, 2006, Modeling of 16. Li J, Yang J, Hu S, 2023, Malignant peritoneal mesothelioma
rd
mesothelioma growth demonstrates weaknesses of current with butterfly-shaped muscle metastasis: 68Ga-FAPI PET/
response criteria. Lung Cancer, 52: 141–148. CT versus 18F-FDG PET/CT. Clin Nucl Med, 48: 348–350.
https://doi.org/10.1016/j.lungcan.2005.12.013 https://doi.org/10.1097/RLU.0000000000004575
10. Ceresoli GL, Chiti A, Zucali PA, et al., 2007, Assessment of 17. Guzel Y, Komek H, Can C, et al., 2023, Comparison of the
tumor response in malignant pleural mesothelioma. Cancer role of 18 F-fluorodeoxyglucose PET/computed tomography
Treat Rev, 33: 533–541. and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with
https://doi.org/10.1016/j.ctrv.2007.07.012 malignant mesothelioma. Nucl Med Commun, 44: 631–639.
11. Lopci E, Zucali PA, Ceresoli GL, et al., 2015, Quantitative https://doi.org/10.1097/MNM.0000000000001702
analyses at baseline and interim PET evaluation for 18. Hu K, Wang L, Wu H, et al., 2022, [18F]FAPI-42 PET
response assessment and outcome definition in patients imaging in cancer patients: Optimal acquisition time,
with malignant pleural mesothelioma. Eur J Nucl Med Mol biodistribution, and comparison with [68Ga]Ga-FAPI-04.
Imaging, 42: 667–675. Eur J Nucl Med Mol Imaging, 49: 2833–2843.
https://doi.org/10.1007/s00259-014-2960-y https://doi.org/10.1007/s00259-021-05646-z
12. Spitilli MG, Treglia G, Calcagni ML, et al., 2007, Malignant 19. Shu Q, Deng M, Hu M, et al., 2023, The additional role of
pleural mesothelioma: Utility of 18 F-FDG PET. Ann Ital [68Ga]Ga-FAPI-04 PET/CT in patients with unknown
Chir, 78: 393–396. primary lesion with a negative or equivocal [18F]FDG. Eur J
Nucl Med Mol Imaging, 50: 1442–1452.
13. Sandach P, Seifert R, Fendler WP, et al., 2022, A role for
PET/CT in response assessment of malignant pleural https://doi.org/10.1007/s00259-022-06095-y

Volume 1 Issue 2 (2023) 5 https://doi.org/10.36922/arnm.0963